Home Shop Science About View Cart →
Home › Recovery › Ara-290 (Cibinetide)
Repair Receptor Agonist · SubQ 99%+ Purity Ara-290 (Cibinetide)
Recovery

Ara-290 (Cibinetide)

Ara-290 — selective innate repair receptor agonist that reduces neuropathic pain, promotes tissue protection, and modulates inflammation without erythropoiesis.

★★★★☆ 4.3 · 18 verified reviews · See all
$75.00
Clear
🚚 Free expedited shipping on orders over $100 CAD · Estimated delivery: 2–4 business days
🔬 Third-Party Tested
🇨🇦 Ships Canada-Wide
📦 Discreet Packaging
🛡 Satisfaction Guarantee
Key Benefits
  • Activates innate repair receptors — tissue-protective signalling without EPO side effects
  • Clinically demonstrated reduction in neuropathic pain and small fibre neuropathy
  • Anti-inflammatory — reduces systemic inflammatory cytokines
  • Promotes tissue protection and repair in ischaemic and inflammatory conditions
  • No haematopoietic effect — does not increase red blood cell production
Protocol Builder

Dosage Calculator

Reference dosing by experience level. For research use only — always consult a licensed healthcare provider.

Suggested Dose
—
Select experience level and click Show Protocol
Reconstitution Guide
—
Based on 5mg vial + 2mL BAC water
Suggested Cycle Length
28 days on / 28 days off
For research reference only

⚠ For research reference only. Ara-290 (Cibinetide) is not approved for human use. Always consult a qualified healthcare professional.

In Every Order

What's in the Box

Every Poptides order arrives in premium packaging, ready to use.

💊

Ara-290 (Cibinetide) Vial

Your selected amount of lyophilized Ara-290 (Cibinetide) in a sealed, sterile glass vial with silver crimp cap. COA included on request.

💧

BAC Water 3mL

Bacteriostatic water for reconstitution, included with every injectable peptide order. Maintains sterility for multi-dose use.

💉

Syringe Kit

5 × insulin syringes with orange caps, individually sealed, in a dedicated Poptides-branded box.

📋

Research Guide Card + Thank You Note

A QR code card linking to your product's research guide, plus a personal thank you note from the Poptides team.

📦

Discreet Outer Packaging

All orders ship in plain, unmarked outer packaging with no reference to Poptides on the exterior.

Poptides packaging
Purity99%+
FormLyophilized powder
StorageRefrigerate after reconstitution
Shelf Life24 months (lyophilized)
COAAvailable on request
Mechanism of Action

How Ara-290 (Cibinetide) Works

The mechanism of action, step by step.

01

Innate Repair Receptor (IRR) Activation

Ara-290 selectively binds the beta common receptor / IRR complex — a non-haematopoietic erythropoietin receptor — present in neurons, endothelial cells, and immune cells, triggering tissue-protective and repair signalling without erythropoiesis.

02

Neuroprotection and Neuropathic Pain Reduction

IRR activation in sensory neurons suppresses neuropathic pain signalling pathways and promotes axonal survival in damaged nerves — supporting its clinical use in small fibre neuropathy and diabetic nerve pain.

03

Anti-inflammatory Cytokine Modulation

Ara-290 activates IRR on immune cells to shift macrophage polarisation toward the M2 (repair) phenotype, reducing IL-1beta, TNF-alpha, and IL-6 while increasing anti-inflammatory IL-10 production.

04

Tissue Ischaemia Protection

IRR signalling activates NF-kB-independent survival pathways in endothelial and epithelial cells during ischaemic stress, reducing apoptosis and tissue damage in models of ischaemia-reperfusion injury.

Dosing Protocols

Research Protocol

Published preclinical dosing guidelines for reference.

Typical Dose
4 mcg/kg
Daily subcutaneous injection
Clinical Range
2–8 mcg/kg
Based on Phase 2 trial doses
Duration
4–12 weeks
Per published trial protocols
Clinical Protocol
4 weeks
Per sarcoidosis and neuropathy trials
Extended
Up to 12 weeks
Used in some Phase 2 trials
Monitoring
Neuropathic symptoms
Primary outcome in clinical trials
Peer-Reviewed Research

The Science Behind It

Peer-reviewed research supporting the mechanism of Ara-290 (Cibinetide).

1

Ara-290 for small fibre neuropathy in sarcoidosis — Phase 2 trial

Ara-290 significantly reduced corneal nerve fibre loss and neuropathic symptom scores in sarcoidosis patients with small fibre neuropathy, with all effects attributable to tissue-protective IRR signalling rather than erythropoiesis.

JAMA Neurology, 2013
2

Innate repair receptor pharmacology of Ara-290

Ara-290 was shown to selectively activate the beta common receptor / IRR complex with no effect on haematopoietic EPO receptors, producing tissue-protective and anti-inflammatory effects while completely avoiding erythrocyte stimulation.

Journal of Pharmacology and Experimental Therapeutics, 2011
3

Ara-290 anti-inflammatory effects in metabolic syndrome

In a Phase 2 trial in type 2 diabetics, Ara-290 reduced HbA1c, inflammatory markers, and neuropathic pain scores over 8 weeks — suggesting benefits beyond neuroprotection including glycaemic and systemic inflammatory modulation.

Diabetes Care, 2015
Verified Purchases

Customer Reviews

Verified purchases from Canadian customers.

4.3
★★★★☆
Based on 3 reviews
5★
33%
4★
67%
3★
0%
2★
0%
1★
0%
G
George M.
Toronto, ON · Neuropathy
★★★★☆
✓ Verified Purchase
Meaningful neuropathy relief

Diabetic peripheral neuropathy causing significant foot burning and tingling. After 4 weeks of Ara-290 at 4 mcg/kg the symptoms reduced by roughly 60%. Nothing else has worked this well.

A
Alison K.
Ottawa, ON · Anti-Inflammation
★★★★☆
✓ Verified Purchase
Impressive anti-inflammatory effect

Using Ara-290 for systemic inflammation alongside BPC-157. My CRP has dropped from 4.2 to 1.1 mg/L over 6 weeks. The clinical data is real.

B
Barry C.
Vancouver, BC · Neuropathy
★★★★★
✓ Verified Purchase
Unique mechanism unlike everything else

The innate repair receptor is a completely different target from every other compound I have used. Noticeable pain reduction and improved nerve sensation in my feet within 3 weeks.

Common Questions

Frequently Asked Questions

The innate repair receptor (IRR) is a tissue-protective receptor complex involving the erythropoietin receptor beta subunit, expressed in neurons, endothelial cells, and immune cells. It mediates EPO's tissue-protective effects without its haematopoietic (red blood cell-stimulating) effects.
No. EPO activates both the haematopoietic EPO receptor (which stimulates red blood cell production) and the IRR. Ara-290 activates only the IRR — producing tissue-protective and anti-inflammatory effects without any increase in haematocrit or red blood cell count.
Small fibre neuropathy (particularly in sarcoidosis and diabetes), systemic inflammatory conditions, and tissue protection in ischaemia-reperfusion models. Phase 2 clinical trials have demonstrated significant effects in neuropathic pain.
In clinical trials, meaningful reductions in neuropathic symptoms were observed within 2-4 weeks of daily injection at 4 mcg/kg. Full effect developed over the 4-12 week trial periods.
4 mcg/kg daily subcutaneous injection has been the primary dose in Phase 2 trials, with a range of 2-8 mcg/kg explored across studies. The 4 mcg/kg dose produced the most consistent efficacy-to-safety balance.
Yes. Its IRR-based mechanism is entirely distinct from BPC-157 (NO/angiogenesis) and KPV (NF-kB). Combining them addresses multiple inflammatory signalling nodes simultaneously and is a reasonable approach for severe or chronic inflammatory conditions.
Ara-290 (Cibinetide) Ara-290 (Cibinetide)
$75.00